| How we diagnose Myelodysplastic syndromes |
|
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Is blood transfusion safe during the COVID-19 pandemic? |
|
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
|
Haematologica |
Aplastic Anemia |
| Diagnosis of myelodysplastic syndromes: the classic and the novel |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Genome sequencing in the management of myelodysplastic syndromes and related disorders |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Treatment of lower-risk myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study |
|
Haematologica |
Aplastic Anemia |
| Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
